GETTING TO THE ROOT OF CHRONIC PAIN

Uncovering the biochemical origins of a patient’s chronic pain can suggest relevant, personalized treatment approaches

Cactus

FOUNDATION PAIN INDEX

77% of these chronic pain patients exhibited at least one abnormal pain biomarker from a large, retrospective, observational study of 17,834 patients with chronic pain

Correction of abnormal levels of functional pain biomarkers using safe, cost-effective therapies could increase the likelihood of successful and prolonged chronic pain management

Personalized recommendations for adjunctive therapy based on the test results

Ethos Laboratories has harnessed the power of these biomarkers to facilitate the personalized assessment and treatment of chronic pain

Pain Index Score

A pain index score that quantifies—in a single number—the
collective results of 11 different biomarker tests.

Individual test results, both current and historic, that enable providers to identify changes in a patient’s functional biomarkers over time and in response to treatment.

The identification and validation of objective biomarkers to aid in the diagnosis and treatment of chronic pain has the potential to reshape pain management paradigms, improve patient outcomes, reduce opioid reliance, cut healthcare costs, and further the pursuit of personalized medicine.

Biomarker Results

This is supported by a large, retrospective, observational study in which 17,834 patients with chronic pain exhibited at least one abnormal pain biomarker.

In contrast, among healthy people with no history of chronic pain or opioid use, only up to 5% exhibited one or more of these abnormal biomarkers.